DYNDyne Therapeutics, Inc.
18.66USD-2.66%Mkt Cap: 3.07B USDP/E: Last update: 2026-06-01

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle…

Indicators:|

Key Statistics

Company
Market Cap3.07B USD
Enterprise Value2.39B USD
Revenue (TTM)
Gross Profit
Net Income (TTM)-446.21M USD
Revenue/Share
Last Price18.66 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees263
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-6.48
PEG
EV/EBITDA-5.10
EV/Revenue
P/S
P/B3.28
EPS (TTM)-3.15
EPS (Forward)-2.98
52W Range
8.06063% of range25.00
52W High25.00 USD
52W Low8.060 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.90%
ROA-37.59%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-403.21M USD
CapEx (TTM)20.71M USD
FCF Margin
FCF Yield-9.51%
Net Debt-803.48M USD
Net Debt/EBITDA1.71
Balance Sheet
Debt/Equity0.17
Current Ratio19.92
Quick Ratio18.97
Book Value/Sh5.893 USD
Cash/Share5.881 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)38.25 USD
Target Range17.00 USD50.00 USD
# Analysts16
Ownership
Shares Out.165.31M
Float164.74M
Insiders0.28%
Institutions115.48%
Short Interest
Short Ratio13.1d
Short % Float16.84%
Short % Out.12.69%
Shares Short20.98M
Short (prev mo.)21.70M
Technical
SMA 5018.25 (+2.2%)
SMA 20017.26 (+8.1%)
Beta1.08
S&P 52W Chg27.94%
Avg Vol (30d)1.39M
Avg Vol (10d)1.45M
Technical Indicators
RSI (14)58.6
MACD0.0211
MACD Signal-0.1617
MACD Hist.+0.1829
BB Upper19.37 USD
BB Middle17.82 USD
BB Lower16.26 USD
BB Width17.47%
ATR (14)0.9937 USD
Vol Ratio (20d)0.61x